Advertising, patient decision making, and self-referral for computed tomographic and magnetic resonance imaging

Archives of Internal Medicine

Volumn 164, Issue 22, 2004, Pages 2415-2419

  Illes, Judy ^a,b   Kann, Dylan ^a,b   Karetsky, Kim ^a   Letourneau, Phillip ^a   Raffin, Thomas A ^a   Schraedley Desmond, Pamela ^b   Koenig, Barbara A ^a,b   Atlas, Scott W ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSUMER; EMOTION; HEALTH PROMOTION; HEALTH SERVICE; MARKETING; MASS MEDIUM; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PRIORITY JOURNAL; SELF CARE;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH;

ADVERTISING; DECISION MAKING; MAGNETIC RESONANCE IMAGING; PATIENTS; PHYSICIAN SELF-REFERRAL; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 10344253822     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.22.2415     Document Type: Article

References (31)

1. Prescription Drug Advertising 21 CFR §202:1.
2. Illes J, Fan E, Koenig BA, Baffin TA, Kann D, Atlas SW. Self-referred whole body imaging: current implications for health care consumers. Radiology. 2003; 228:346-351.
3. Feedback Research Services. Cardiac & Preventive Scanning Markets: Service and System Revenues. Jacksonville, Ore: Feedback Research Services; 2001.
4. Fuchs V. The growing demand for medical care. N Engl J Med. 1968;279:190-195.
5. Koenig BA. The technological imperative in medical practice: the social creation of a routine treatment. In: Lock M, Gordon D, eds, Biomedicine Examined. Boston, Mass: Kluwer; 1988:465-496.
6. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion? N Engl J Med. 2002;346:524-526.
7. Terzian T. Direct-to-consumer prescription drug advertising. Am J Law Med Ethics. 1999;25:149-167.
8. Duke CR, Pickett GM, Carlson L, Groe SJ. A method for evaluating the ethics of fear appeals. J Public Policy Marketing. 2001;12:120-129.
9. Arthur D, Wuester P. The ethicality of using fear for social advertising. Australias Marketing J. 2003;11:12-27.
10. Everett SE. Lay audience response to prescription drug advertising. J Advert Res. 1991;April/May:43-49.
11. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA. 2002;288:1762-1767.
12. Gollust SE, Wilfond BS, Hull SC. Direct-to-consumer sales of genetic services on the internet. Genet Med. 2003;5:332-337.
13. Cho MK, Arruda M, Holtzman NA. Educational material about genetic tests: does it provide key information for patients and practitioners? Am J Med Genet. 1997; 73:314-320.
14. Risk A, Petersen C. Health information on the internet: quality issues and international initiatives. JAMA 2002;287:2713-2715.
15. American Medical Association. Current Opinions of the Judicial Council of the AMA. Chicago, III: American Medical Association; 1982:sect 8.07.
16. Rotzoll K, Haefner J. Advertising in Contemporary Society. Urbana: University of Illinois Press; 1996.
17. Food and Drug Administration. Guidance for industry: consumer-directed broadcast advertisements. 62 Federal Register 43-171 (1991).
18. Mitchell JM, Scott E. New evidence of the prevalence and scope of physician joint ventures. JAMA. 1992;268:80-84.
19. Lumpkin JR, Festervand TA. Purchase information source of the elderly. J Advert Res. 1987;27:31-43.
20. Strutton DD, Lumpkin JR. Information sources used by elderly health care product adopters. J Advert Res. July/August 1992:20-30.
21. Federal Trade Commission. FTC Policy Statement on Deception. 45, Antitrust and Trade Regulatory Report; October 27,1983. Available at: http://www.ftc.gov/bcp /policystmt/ad-decept.htm. Accessed November 5, 2003.
22. Denzin NK, Lincoln YS, eds. Handbook of Qualitative Research. Thousand Oaks, Calif: Sage Publications; 1994.
23. Shiv B, Edell JA, Payne JW. Factors affecting the impact of negatively and positively framed ad messages. J Consum Res. 1997;24:285-294.
24. Federal Trade Commission Act. Section 12, 15 USC §52.
25. Lee TH, Brennan TA. Direct-to-consumer marketing of high technology screening tests. N Engl J Med. 2002;346:529-531.
26. US Food and Drug Administration. Whole body scanning: using computed tomography (CT). Available at: www.fda.gov/cdrh/ct. Accessed Novembers, 2003.
27. Brant-Zawadzki M. CT screening: why I do it. AJR Am J Roentgenol. 2002;179: 319-326.
28. Modic MT, Obuchowski N. Whole-body CT screening for cancer and coronary disease: does it pass the test? Cleve Clin J Med. 2004;71:47-56.
29. Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with fullbody CT screening. Radiology. 2004;232:735-738.
30. Le Heron JC, Coakley KS. CT screening: whole-body and targeted. Australas Phys Eng Sci Med. 2004;27:1-4.
31. Morris LA, Brinberg D, Klimberg R, Rivera C, Millstein LG. Miscomprehension rates for prescription drug advertisements. Curr Issues Res Advert. 1986;9: 93-117.